

ARE ALDOSTERONE ASSAYS BY LC-MS/MS HARMONISED IN AUSTRALIA?

ZX Lu,^{1,2} J Liao,¹ K Liu,¹ K Mantik,³ K Hoad,⁴ B McWhinney,⁵ R Sahertian,³ GRD Jones,⁶ M Gillett,⁴ J Ungerer,⁵ AR Horvath³

¹Monash Health Pathology, VIC; ²Department of Medicine, Monash University, VIC; ³NSW Health Pathology, NSW; ⁴PathWest Laboratory Medicine WA; ⁵Pathology Queensland, QLD; ⁶SydPath, St Vincent's Hospital, NSW.

Zhong.lu@monashhealth.org

Introduction

Accurate measurement of aldosterone is crucial for the investigation of primary aldosteronism. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) provides better selectivity over immunoassays by avoiding cross-reactivity with other steroid compounds that have similar structure to aldosterone. We compared the analytical performance of LC-MS/MS aldosterone assays in Australia in view of harmonising reference intervals and diagnostic decision limits.

Methods

Aliquots from 30 de-identified clinical samples with aldosterone concentrations ranging from 27 - 2600 pmol/L, were sent to four laboratories.

LCMS/MS analysers used:

- Lab1: Sciex QTRAP 5500; Lab2: Sciex QTRAP 6500+
- Lab3: Waters Xevo TQ-S micro; Lab4: Waters Xevo TQ-S.

Calibrators:

Laboratories used either commercial calibrators (Chromsystems) or in-house calibrators prepared by spiking aldosterone standard (Cerilliant) into stripped serum (Golden West).

Acceptance criteria :

Mean results of the four methods were used for comparison. RCPAQAP analytical performance specifications (APS) (± 24 up to 160; $\pm 15\%$ >160 pmol/L) were used as acceptance limits.

The precision goal for analytical CV (Cv_a) was defined using within-subject biological variation (CV_i) of 36.6%¹: optimal = $0.25 \times CV_i$ = 9.1%; desirable = $0.5 \times CV_i$ = 18.3%; minimal = $0.75 \times CV_i$ = 27.4%.²

Precision of the assays:

Cv_a was calculated for each sample using results from the four laboratories. Results from one sample with an interference peak was excluded.

A precision profile was generated by plotting Cv_a values for each sample against the corresponding aldosterone concentrations.

Results




Fig 1. Patient correlation of aldosterone by LCMS/MS results

Compared to the mean, $r^2 > 0.997$ was achieved by all laboratories. The Passing-Bablok equation for each laboratory compared to the mean was:

- Lab1 = $1.028 \times \text{mean} - 2.6$;
- Lab2 = $0.975 \times \text{mean} + 5.2$;
- Lab3 = $0.997 \times \text{mean} + 2.2$;
- Lab4 = $0.970 \times \text{mean} + 2.2$.




Fig 2. Difference plot of all aldosterone by LCMS/MS results vs mean

All results (except two) were within the mean \pm APS for each sample. One of the outliers was found to have a method-dependent interference peak.




Fig 3. Precision profile using combined data from all laboratories

For all the samples (except one) with aldosterone >70 pmol/L the Cv_a achieved the optimal precision goal of $\leq 9.1\%$, adding only less than 3% of variability in test results seen in the patient, according to the chart for Result Variability vs Ratio of Analytical Imprecisions to Within-subject Biological Variation by Callum Fraser.²

At around 160 pmol/L, a proposed cut-off for positive saline suppression test in the Harmonisation of Endocrine Dynamic Testing-Adult (HEDTA) protocol,³ the Cv_a was $\sim 7\%$.

Cv_a for aldosterone < 70 pmol/L was higher (10-28%) but still met at least the minimal precision goal.

Discussion and Conclusion

This study in commutable specimens showed that there is good agreement in aldosterone results by the LC-MS/MS methods from four different laboratories. This paves the way for moving towards national harmonisation of the reference intervals and clinical decision limits for aldosterone by LC-MS/MS in Australia.

Further collaboration is required for all the laboratories to work together to harmonise their method, reference intervals and decision limits used in the diagnostic pathway of primary aldosteronism.

References:

1. EFLM Biological Variation Database: <https://biologicalvariation.eu/>
2. Fraser CG. 2001, Biological variation from principles to practice. AACCC Press, Washington. Page 51.
3. Chiang C et al. 2021, Harmonisation of Endocrine Dynamic Testing-Adult (HEDTA) protocol. Available at <https://www.aacb.asn.au/documents/item/5429>.